Activity assays metabolites

In vitro activity assay (for pharmacological activity Activity of the metabolite toward the therapeutic target is determined in vitro with a purified sample. Sometimes, the 0.1-10 mg Mammalian or Microbial bioreactors... 

In the search for nonisotopic HDAC substrates, different fluorescence-labeled substrates have been developed, allowing for a convenient nonradioactive assay. The first described fiuorescence-based HDAC activity assay [21] uses the lysine-derived deacetylase substrate Boc(Ac)Lys-AMC, also called MAL (Figure 5.1). The incubation with a histone deacetylase preparation shows time-dependent conversion into its metabolite ML. 

With respect to higher-throughput analytical methodologies, we have taken two approaches. The first involves the addition of CYP-selective substrates to cell culture and measuring the formation of the relevant metabolites in the media (CYP activity assays). The second approach is to measure CYP mRNA levels using newly developed technologies compatible with 96-well culture formats. 

Figure 4 Structures of common microbial metabolites active in the macrophage activation assay...

Active secondary metabolites are often deterrent to more than one predator. Algal secondary metabolites have been shown to deter both sea urchins and fish [67]. Compounds from a Bahamian sponge deter feeding among a natural assemblage of fish [68]. Ascidlans have also been shown to contain a chemical defence against reef fish in field assays [61]. 

As to the potential link of omega-3 PUFA-derived mediators to NFkB activity, Arita et al. showed, by using a NFkB luciferase activation assay, that the EPA-derived resolvin El (RvEl) was able to inhibit TNF-a induced NFkB activation (Arita et al., 2005a). This suggests that omega-3 PUFA metabolites may be able to directly regulate the expression of NFkB associated genes. 

Although active, hydroxylated metabolites are not assayed routinely because there is no cnrrent evidence to snggest that their measurement yields any useful information for the clinical management of depression. No dose alterations are necessary in patients with decreased renal fnnction. 

However, activity assays may serve as a more rationale approach to the exploration of active metabolites. This is most often and most effectively done in the setting of an in vivo efficacy experiment that allows for both pharmacodynamic and pharmacokinetic information to be gathered. Analysis of the relationship between the PD endpoint and the PK profile will sometimes demonstrate an apparent disconnect between the two data sets and point to the possibility that an active metabolite is responsible for some of the activity. These disconnects can serve as clear trigger points for the initiation of active metabolite searches. 

Lovastatin is an inactive prodrug which undergoes in vivo lactone hydrolysis to give the hydroxyacid derivative which is an inhibitor of HMG-CoA reductase. The pharmacokinetic and metabolic profile of lovastatin has been described in detail (3,5,35-37). In the sections below, the absorption, distribution, metabolism, and excretion of lovastatin are briefly reviewed. For this discussion it is helpful to distinguish between active inhibitors (defined as the sum concentration of the hydroxyacid derivative of lovastatin plus other active hydroxyacid metabolites) and total inhibitors (the total concentration of active inhibitors plus lactones and conjugates). Active and totai inhibitors can be separately quantitated by assaying samples before and after ex vivo hydrolysis of plasma samples. 

The diagnosis of fatty acid oxidation defects can be made by recognition of typical metabolites, by functional assays, by specific enzyme activity assays, and by molecular analysis. A primary test... 

The active drug and metabolites can be detected from the urine by thin-layer chromatography, gas-liquid chromatography, or gas chromatography-mass spectrometry. However, assays are available only at specialized centers. Treatment of acute intoxication with mescaline is virtually identical to the treatment outlined for LSD intoxication. DOM-induced vasospasm responds well to intra-arterial tolazohne or sodium nitroprusside. Major life-threatening complications of hallucinogenic amphetamine derivatives include hyperthermia, hypertension, convulsions, cardiovascular collapse, and self-inflicted trauma. 

Agarwal et al. 1978), the quantification of these specific enzymes may indicate that exposure to endosulfan has occurred. Blood tests, such as decay curves for aminopyrine in plasma, which are semiquantitative indices of liver enzyme induction, have been used successfully in the past to demonstrate enzyme induction in pesticide-exposed workers. Because numerous chemicals found at hazardous waste sites also induce these hepatic enzymes, these measurements are not specific for endosulfan exposure. However, measurements of enzyme activity, together with the detection of the parent compound or its metabolites in tissue or excreta, can be useful indicators of exposure. All of these potential biomarkers require further verification in epidemiological studies. Further studies with focus on the development of methods to separate and measure the estrogenicity of endosulfan in in vitro assays would be valuable since these assays are more sensitive and discriminative than other conventional biomarkers. Preliminary results have been presented by Sonnenschein et al. (1995). 

The 25-OH-D Is further metabolized In the kidney to 1,25 dlhydroxycholecalclferol (1,25(OH)2D) which Is considered to be the major physiologically Important, tissue-active metabolite of vitamin D. It circulates In extremely low concentrations (< 100 pg/ml of serum). Assay of 1,25(OH)2D Is extremely tedious. It Is done by competitive binding technique using a combined Intestinal cell cytosol and chromatin binding system, biosynthetic 3h-1,25(OH)2D3 as labeled ligand and synthetic 1,25(0H)2D3 as standard (31). 

The basic clinical tool used at the present time Is the competitive ligand binding assay for 25-OH-D. Although concentrations are low In the serum of patients with osteomalacia and v . tamln D deficiency rickets, we have recently noted the Interesting paradox that levels can be only 1/2 normal In the face of oyert bone disease (32). This had led us to propose that substrate levels of 25-OH-D3 available to the hydroxylase In kidney which Is responsible for the conversion of 25-OH-D3 to the tissue active metabolite, l,25(OH)2D3, may be rate limiting for this enzyme. 

---